Mp48-06 patient-reported treatment burden of intravesical therapy for bladder cancer

The Journal of Urology(2023)

引用 0|浏览6
暂无评分
摘要
You have accessJournal of UrologyCME1 Apr 2023MP48-06 PATIENT-REPORTED TREATMENT BURDEN OF INTRAVESICAL THERAPY FOR BLADDER CANCER Amanda Myers, Benjamin Ristau, Matthew Mossanen, Deborah Kaye, Mark Tyson, Stephanie Chisolm, Frank Sloan, Colleen Ball, Angela Smith, and Timothy Lyon Amanda MyersAmanda Myers More articles by this author , Benjamin RistauBenjamin Ristau More articles by this author , Matthew MossanenMatthew Mossanen More articles by this author , Deborah KayeDeborah Kaye More articles by this author , Mark TysonMark Tyson More articles by this author , Stephanie ChisolmStephanie Chisolm More articles by this author , Frank SloanFrank Sloan More articles by this author , Colleen BallColleen Ball More articles by this author , Angela SmithAngela Smith More articles by this author , and Timothy LyonTimothy Lyon More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003294.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Intravesical therapy is the mainstay of treatment for non-muscle invasive bladder cancer (NMIBC). However, patients with NMIBC can face time, travel, and financial barriers to access intravesical therapy which may impact patient adherence to treatment. Therefore, we sought to quantify patient-reported treatment burden while receiving intravesical therapy for bladder cancer. METHODS: We conducted a cross-sectional survey of bladder cancer patients in the Bladder Cancer Advocacy Network (BCAN) Patient Survey Network to investigate patient-reported burden of intravesical therapy. Multiple choice survey questions were developed by investigators, then iteratively revised and improved by review from clinician and patient advocate stakeholders during the 2021 BCAN annual meeting. Eligible participants received at least one dose of intravesical therapy, including BCG and/or chemotherapy, delivered in an ambulatory setting. Survey was administered in November 2021 and was available for 1 month to respondents. RESULTS: A total of 233 patients responded to the survey (18% response rate), with a median age of 70 years (range 33-88). Respondents were 36% female and 97% white. A travel time >30 minutes to an intravesical treatment facility was reported by 55% (126/231) of patients, and 33% (77/231) reported personal out-of-pocket costs greater than $25 associated with each trip. Fifty-six percent (129/232) brought caregivers to their appointments. More than half of patients (56%, 129/232) reported spending more than 2 hours on each intravesical instillation, with 18% (42/232) spending more than 4 hours. Missing work for intravesical installations was reported by 36% (82/230) of patients, and of those who did, the majority (70%, 57/81) missed at least half a day of work (4 or more hours). Sixty-one respondents (26%) felt the process of receiving bladder instillations adversely affected their ability to perform regular daily activities. BCG shortages increased travel or wait time for intravesical therapy for 9% (20/229) of respondents. CONCLUSIONS: Bladder cancer patients reported considerable travel distances, time requirements, out-of-pocket costs, and need for caregiver support in the process of receiving intravesical therapy. Innovative intravesical care delivery processes are needed to reduce the burden of care for our bladder cancer patients. Source of Funding: n/a © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e657 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Amanda Myers More articles by this author Benjamin Ristau More articles by this author Matthew Mossanen More articles by this author Deborah Kaye More articles by this author Mark Tyson More articles by this author Stephanie Chisolm More articles by this author Frank Sloan More articles by this author Colleen Ball More articles by this author Angela Smith More articles by this author Timothy Lyon More articles by this author Expand All Advertisement PDF downloadLoading ...
更多
查看译文
关键词
bladder,intravesical therapy,treatment burden,cancer,patient-reported
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要